NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Analysts
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the […]
More Stories
Chanson International (NASDAQ:CHSN) versus Nestlé (OTCMKTS:NSRGY) Critical Survey
Nestlé (OTCMKTS:NSRGY – Get Free Report) and Chanson International (NASDAQ:CHSN – Get Free Report) are both consumer staples companies, but...
Arctic Star Exploration (CVE:ADD) Trading Up 50% – Still a Buy?
Shares of Arctic Star Exploration Corp. (CVE:ADD – Get Free Report) shot up 50% during mid-day trading on Saturday ....
Head to Head Comparison: iTeos Therapeutics (NASDAQ:ITOS) & Invivyd (NASDAQ:IVVD)
Invivyd (NASDAQ:IVVD – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but...
Oracle Power (LON:ORCP) Trading Down 14.3% – Here’s Why
Oracle Power plc (LON:ORCP – Get Free Report)’s share price traded down 14.3% during mid-day trading on Saturday . The...
Protagenic Therapeutics, Inc. Enters into Amendment No. 1 to At Market Issuance Sales Agreement
On January 9, 2025, Protagenic Therapeutics, Inc. announced that it has entered into Amendment No. 1 to the At Market...
Weather, Power, and Water Issues Persist in Los Angeles’ Eaton Fire Area
By Beige Luciano-Adams LOS ANGELES—Residents eager to return home and survey vast damage wrought by the Eaton Canyon Fire in...